Amgen, Servier in $50m cardiovascular deal

Amgen has announced a new collaboration agreement with French research-based pharma company, Servier, which will leverage each company’s commitment to cardiovascular disease.

Under terms of the agreement, Amgen has obtained commercial rights in the US to Servier’s novel oral drug, Procoralan (ivabradine), which has been approved in the EU for chronic heart failure and stable angina in patients with elevated heart rates. Amgen will make a one-time US $50 million upfront payment to Servier, as well as future milestone payments for ivabradine.

“Amgen is pleased to enter into this collaboration with Servier to bring potential new cardiovascular treatment options to patients in both the U.S. and Europe. A critical unmet medical need remains for patients who don’t respond adequately to current available therapies for heart failure and angina. Ivabradine, an Ifinhibitor, offers a novel alternative approach for patients with elevated heart rates. We value Servier’s extensive experience in cardiovascular disease and look forward to working with them as Amgen continues to build our presence in this area.”

Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

Amgen has also received an exclusive option to develop and commercialize Servier’s investigational molecule, S38844, for cardiovascular diseases in the US. The molecule is currently in phase 2 clinical trials for the treatment of heart failure.

Related news:

Amgen commits $50M-plus in 3-way deal to expand cardiovascular drug pipeline (FierceBiotech)

Reference links:

Amgen press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.